MedTrace Logo

Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer

NCT07012720 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2025-06-10

No results posted yet for this study

Summary

This study is a single-center, open-label, prospective, clinical cohort study. It enrolled patients in three subgroups: triple negative, HR+HER2-, or HR-HER2+ subtypes, who will receive neoadjuvant treatment according to guidelines. Patients in each subgroup will be divided into two categories: those responsive to neoadjuvant therapy and those resistant to it, based on the efficacy of the treatment. Tumor tissue samples from all enrolled patients before and after neoadjuvant therapy will be collected. We will explore transcriptomic differences in neoadjuvant therapy responders or resisters under the same treatment regimen, as well as transcriptomic changes in tumor tissue before and after treatment, based on single-cell sequencing and spatial transcriptomic technology.

Conditions

Interventions

DIAGNOSTIC_TEST

Single-cell sequencing and spatial transcriptome

Tumor tissue samples of all enrolled patients before and after neoadjuvant therapy were collected. Based on single-cell sequencing and spatial transcriptome technology, the transcriptomic differences in neoadjuvant therapy response or treatment resistance under the same treatment regimen, as well as the transcriptomic changes of tumor tissues before and after treatment were explored.

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2026-04-30
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07012720 on ClinicalTrials.gov